Analyst Ratings For Krystal Biotech Inc (NASDAQ:KRYS)
Today, Cowen initiated coverage on Krystal Biotech Inc (NASDAQ:KRYS) with a Outperform.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Krystal Biotech Inc (NASDAQ:KRYS) is Buy with a consensus target price of $35.00 per share, a potential 46.26% upside.
Some recent analyst ratings include
- 12/12/2018-Krystal Biotech Inc (NASDAQ:KRYS) has coverage initiated with a Outperform rating
- 11/5/2018-Krystal Biotech Inc (NASDAQ:KRYS) had its Buy rating reiterated by HC Wainwright with a $32.00 price target
- 11/5/2018-Krystal Biotech Inc (NASDAQ:KRYS) had its Buy rating reiterated by William Blair
- 10/15/2018-Krystal Biotech Inc (NASDAQ:KRYS) had its Buy rating reiterated by Cantor Fitzgerald with a $35.00 price target
- 8/6/2018-Krystal Biotech Inc (NASDAQ:KRYS) had its Buy rating reiterated by Chardan Capital with a $35.00 price target
- On 10/18/2018 Krish S Krishnan, Insider, bought 25,000 with an average share price of $20.00 per share and the total transaction amounting to $500,000.00.
- On 6/6/2018 Suma Krishnan, COO, bought 25,000 with an average share price of $11.02 per share and the total transaction amounting to $275,500.00.
- On 5/22/2018 Antony A Riley, CFO, bought 2,800 with an average share price of $10.75 per share and the total transaction amounting to $30,100.00.
- On 5/9/2018 R Douglas Norby, Director, bought 9,000 with an average share price of $10.42 per share and the total transaction amounting to $93,780.00.
- On 3/19/2018 Krish S Krishnan, Insider, bought 50,000 with an average share price of $11.00 per share and the total transaction amounting to $550,000.00.
- On 9/22/2017 Daniel Janney, Director, bought 200,000 with an average share price of $10.00 per share and the total transaction amounting to $2,000,000.00.
- On 9/22/2017 Suma Krishnan, COO, bought 100,000 with an average share price of $10.00 per share and the total transaction amounting to $1,000,000.00.
About Krystal Biotech Inc (NASDAQ:KRYS)
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Recent Trading Activity for Krystal Biotech Inc (NASDAQ:KRYS)
Shares of Krystal Biotech Inc closed the previous trading session at 23,93 +0,64 2,75 % with 22.95 shares trading hands.